Staying on 7.5 mg Mounjaro: what the dose-escalation rules really mean

The myth that 7.5 mg is just a waypoint you pass through

The biggest misunderstanding about Mounjaro's dose ladder is that every rung exists to be climbed. People assume the 15 mg dose is the destination and everything below it is merely transit. That is not what the evidence, or the licensed guidance, says.

Tirzepatide is approved in the UK at six strengths: 2.5, 5, 7.5, 10, 12.5 and 15 mg. Each is a fully therapeutic option in its own right. The 2.5 mg starting dose is genuinely different (its primary job is to let your body adjust before weight-loss effects accumulate) but from 5 mg upward the medicine is doing real work. By 7.5 mg, many people are seeing meaningful reductions in appetite and body weight. Our Mounjaro overview covers how the dual GIP and GLP-1 mechanism produces these effects across the dose range.

In SURMOUNT-1, the large phase-3 trial whose results are published in the New England Journal of Medicine, participants on all active doses lost significantly more weight than those on placebo. The 15 mg arm showed the greatest average loss, but that average conceals wide individual variation. Some people achieve their target weight at 7.5 mg, and if you are wondering whether that dose can become a long-term home rather than a stepping stone, our page on staying on 7.5 mg Mounjaro explores exactly that question. Neither outcome is a failure of the dose, it reflects normal biological variation.

The conclusion worth holding onto: if you are losing weight at 7.5 mg and tolerating it well, staying there is clinically reasonable, not a shortcut.

When staying at 7.5 mg makes sense, and when it might not

A prescriber weighing up whether to hold you at 7.5 mg will look at a few things together. Weight loss trajectory matters, is it still moving in the right direction, even slowly? Tolerability matters too. Gastrointestinal side effects (nausea, loose stools, reflux, feeling uncomfortably full) are most pronounced after a dose increase and typically settle within a couple of weeks as the body acclimates. If you are still working through that adjustment phase at 7.5 mg, rushing upward is likely to make things harder rather than faster.

There is also a practical, everyday angle. Some patients find 7.5 mg fits their life neatly, they store the pen in the fridge door, inject once a week, and the routine has become unremarkable. A dose increase resets the adjustment clock. That is not always a reason to avoid it, but it is a legitimate part of the conversation with your prescriber.

On the other hand, if weight loss has genuinely stalled across several weeks at 7.5 mg and side effects are not the barrier, your prescriber may suggest titrating upward. The NICE appraisal of tirzepatide (TA1026) notes that continuing treatment is reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose, which implies that tolerability, not an arbitrary ceiling, determines how far you go.

People who are curious about the parallel question for lower doses can read about staying at 5 mg Mounjaro or the broader context of holding at a lower Mounjaro dose generally.

Side effects at 7.5 mg and what holding your dose can do for them

The gastrointestinal effects of tirzepatide (nausea, queasiness after eating, changes in bowel habits, occasional heartburn) are dose-related and generally most troublesome in the first one to two weeks after stepping up. At 7.5 mg specifically, some people arrive here from 5 mg and find the jump noticeable. Holding at 7.5 mg rather than moving straight to 10 mg gives the body more time to settle before the next adjustment.

This is not an informal workaround. The titration schedule in the Mounjaro SmPC (available on the electronic Medicines Compendium) already allows additional weeks at any dose before increasing, precisely because tolerability varies between individuals. There is nothing in the licensed guidance that penalises a patient for taking longer to titrate.

Fatigue, mild headache and reduced appetite (which is of course partly the intended effect) are also reported at this dose. Most people find these settle. If side effects at 7.5 mg remain significant beyond a few weeks, that is a conversation to have with your prescriber rather than something to manage alone. Severe, persistent stomach pain that extends toward the back warrants urgent medical attention, as it can occasionally indicate pancreatitis; the MHRA highlighted acute pancreatitis as a known risk with GLP-1 medicines in a Drug Safety Update in January 2026.

If you are wondering whether you could move up earlier than the standard interval, the considerations around increasing your Mounjaro dose early are worth reading, they apply in reverse when thinking about holding longer.

How the decision gets made, and where your prescriber fits in

Dose decisions for a prescription-only medicine like Mounjaro are not made by reading a FAQ. They are made by a qualified prescriber who knows your health history, your current weight trajectory and your experience of the treatment so far.

At nume, every repeat supply involves a clinical review before anything is dispensed. A real clinician (a GPhC-registered Independent Prescriber) reads your update, not software. That review is where the question of staying at 7.5 mg versus titrating gets answered properly, with your information in front of someone accountable for the recommendation. There is more on how the clinical team approaches these decisions on our team page.

If you are already established on treatment and have questions between reviews, you can reach our aftercare team seven days a week. And if you are considering starting Mounjaro for the first time, it is also worth understanding that the opening dose has its own questions, including whether staying on 2.5 mg of Mounjaro is ever the right call, before moving on to check your eligibility with a free consultation. No question about dose progression needs to be answered in a vacuum.